Mrinal Gounder1, Ved Desai2, Deborah Kuk3, Narasimhan Agaram4, Maria Arcila4, Benjamin Durham4, Mary L Keohan2, Mark A Dickson2, Sandra P D'Angelo2, Neerav Shukla5, Craig Moskowitz2, Ariela Noy2, Robert G Maki6, Diego Adrianzen Herrera2, Armando Sanchez2, Anita Krishnan2, Andrew Pourmoussa2, Li-Xuan Qin3, William D Tap2. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: gounderm@mskcc.org. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA. 3. Department of Biostatistics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA. 5. Department of Pediatrics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA. 6. Icahn School of Medicine at Mount Sinai, 1428 Madison Avenue, New York, NY, 10029, USA.
Abstract
BACKGROUND: Neoplasms of histiocytic and dendritic cell origin, including follicular dendritic cell sarcoma (FDCS), histiocytic sarcoma (HS) and interdigitating dendritic cell sarcoma (IDCS), are extremely rare, and data on their natural history and treatment outcomes are sparse. We evaluated the impact of surgery, radiation and systemic therapies on overall survival (OS). METHODS: We conducted a retrospective chart review of patients with FDCS, IDCS and HS treated at Memorial Sloan Kettering Cancer Center between 1995 and 2014. RESULTS: We identified 31, 15 and 7 patients with FDCS, HS and IDCS, respectively. Median age was 48.7, 42.3 and 58.8years for FDCS, HS and IDCS, respectively. Only a slight disparity in gender distribution existed for FDCS and HS; however, IDCS predominantly affected males (6:1). The most common sites of presentation were abdomen and pelvis (42%), extremities (33%) and head and neck (57%) for FDCS, HS and IDCS, respectively. At diagnosis, 74%, 40% and 86% of patients presented with localised disease in FDCS, HS and IDCS, respectively. Patients with localised disease had significantly improved OS than those with metastatic disease in FDCS (P=0.04) and IDCS (P=0.014) but not in HS (P=0.95). In FDCS and HS, adjuvant or neo-adjuvant therapy was not associated with improved OS compared with observation. In IDCS, surgery alone provided a 5-year overall survival rate of 71%. CONCLUSIONS: Adjuvant or neo-adjuvant treatment in FDCS and HS did not affect OS. Patients with IDCS had an excellent outcome with surgery. In the metastatic setting, chemotherapy and small molecule inhibitors may provide benefit.
BACKGROUND:Neoplasms of histiocytic and dendritic cell origin, including follicular dendritic cell sarcoma (FDCS), histiocytic sarcoma (HS) and interdigitating dendritic cell sarcoma (IDCS), are extremely rare, and data on their natural history and treatment outcomes are sparse. We evaluated the impact of surgery, radiation and systemic therapies on overall survival (OS). METHODS: We conducted a retrospective chart review of patients with FDCS, IDCS and HS treated at Memorial Sloan Kettering Cancer Center between 1995 and 2014. RESULTS: We identified 31, 15 and 7 patients with FDCS, HS and IDCS, respectively. Median age was 48.7, 42.3 and 58.8years for FDCS, HS and IDCS, respectively. Only a slight disparity in gender distribution existed for FDCS and HS; however, IDCS predominantly affected males (6:1). The most common sites of presentation were abdomen and pelvis (42%), extremities (33%) and head and neck (57%) for FDCS, HS and IDCS, respectively. At diagnosis, 74%, 40% and 86% of patients presented with localised disease in FDCS, HS and IDCS, respectively. Patients with localised disease had significantly improved OS than those with metastatic disease in FDCS (P=0.04) and IDCS (P=0.014) but not in HS (P=0.95). In FDCS and HS, adjuvant or neo-adjuvant therapy was not associated with improved OS compared with observation. In IDCS, surgery alone provided a 5-year overall survival rate of 71%. CONCLUSIONS: Adjuvant or neo-adjuvant treatment in FDCS and HS did not affect OS. Patients with IDCS had an excellent outcome with surgery. In the metastatic setting, chemotherapy and small molecule inhibitors may provide benefit.
Authors: Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins Journal: Blood Date: 2010-06-02 Impact factor: 22.113
Authors: S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss Journal: Histopathology Date: 2002-07 Impact factor: 5.087
Authors: Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons Journal: Blood Date: 2014-09-08 Impact factor: 22.113
Authors: Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen Journal: J Exp Med Date: 2014-03-17 Impact factor: 14.307
Authors: Marilia Takada; Lauren A Smyth; Jeremy Ml Hix; Sarah M Corner; Matti Kiupel; Vilma Yuzbasiyan-Gurkan Journal: Comp Med Date: 2019-02-04 Impact factor: 0.982
Authors: Erica F Andersen; Christian N Paxton; Dennis P O'Malley; Abner Louissaint; Jason L Hornick; Gabriel K Griffin; Yuri Fedoriw; Young S Kim; Lawrence M Weiss; Sherrie L Perkins; Sarah T South Journal: Mod Pathol Date: 2017-06-16 Impact factor: 7.842
Authors: Preetesh Jain; Sarah A Milgrom; Keyur P Patel; Loretta Nastoupil; Luis Fayad; Michael Wang; Chelsea C Pinnix; Bouthaina S Dabaja; Grace L Smith; Jun Yu; Shimin Hu; Carlos E Bueso Ramos; Rashmi Kanagal-Shamanna; L Jeffrey Medeiros; Yasuhiro Oki; Nathan Fowler Journal: Br J Haematol Date: 2017-04-06 Impact factor: 6.998
Authors: Lucas R Massoth; Yin P Hung; Lawrence R Zukerberg; Erik A Williams; Judith A Ferry; Robert P Hasserjian; Valentina Nardi; G Petur Nielsen; Sam Sadigh; Vinayak Venkataraman; Martin Selig; Alison M Friedmann; Wesley Samore; Jonathan Keith Killian; Riza Milante; Joseph Giessinger; Kathleen Foley-Peres; Chelsea Marcus; Eric Severson; Daniel Duncan; Smruthy Sivakumar; Jeffrey S Ross; Vikram Desphande; Shakti H Ramkissoon; Jo-Anne Vergilio; Abner Louissaint Journal: Oncologist Date: 2021-05-06